Cargando…
Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms
BACKGROUND: Guaifenesin is a component of medicines used to improve symptoms associated with upper respiratory tract infections. Patient-reported outcome instruments are valuable for evaluating symptom improvements; however, a validated tool to assess efficacy of mucoactive drugs does not exist. We...
Autores principales: | Albrecht, Helmut, Vernon, Margaret, Solomon, Gail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546880/ https://www.ncbi.nlm.nih.gov/pubmed/23270519 http://dx.doi.org/10.1186/1465-9921-13-118 |
Ejemplares similares
-
Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study
por: Septimus, Edward J., et al.
Publicado: (2017) -
Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection
por: Tripathi, Sanjay, et al.
Publicado: (2019) -
Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections
por: Albrecht, Helmut H., et al.
Publicado: (2017) -
Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years
por: Thompson, Gary A., et al.
Publicado: (2016) -
Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells
por: Seagrave, JeanClare, et al.
Publicado: (2012)